Matches in SemOpenAlex for { <https://semopenalex.org/work/W2950791822> ?p ?o ?g. }
- W2950791822 endingPage "239" @default.
- W2950791822 startingPage "238" @default.
- W2950791822 abstract "Introduction: Analysis of clinical, molecular features and prognostic factors in aggressive histology MCL (AH-MCL; blastoid or pleomorphic) is not described. AH-MCL can be [de novo (dnMCL) or transformed from classic morphology (t-MCL)]. Methods: We reviewed 183 pts with AH-MCL (108 were dn-MCL and 75 were t-MCL). Overall, 152 were blastoid and 31 pleomorphic. Pt characteristics were collected at the time of diagnosis in dnMCL and at transformation. Overall survival (OS) - time of initial diagnosis of AH-MCL to death/last follow-up and failure free survival (FFS) - time of starting first-line treatment of AH-MCL to treatment discontinuation. Whole-exome sequencing (WES) with SureSelect Human All Exon V6 was performed from biopsy samples from 44 pts (dnMCL = 32, t-MCL = 12). Results: Median follow up after diagnosis of AH-MCL was 19.6 months (0.1-168). Clinical features of AH-MCL were - 20% B symptoms, 6% had ECOG PS (3-4), CNS involvement in 4%, 19% with GI involvement, 67% with marrow involvement and 27% had leukemic phase. The median Ki-67% was 70% (10-100), complex karyotype 13%, LDH > ULN in 45%, Sox-11 positive in 81%, median β2M of 2.9 mg/dL. Pts with t-MCL were distinct from dnMCL in having significantly higher median age, poor PS, lower WBC count, lower marrow involvement and lower rate of achieving CR with first line treatments. All pts with t-MCL had prior treatment for MCL before transformation with median lines of prior therapy 2 (range 1-8). The median OS after diagnosis of AH-MCL was 33 months (48 and 14 months for dnMCL and t-MCL respectively; p = 0.001; Figure-1A-B). Univariate and multivariate (MVA) analyses were performed. Recursive partitioning analysis revealed that Ki-67% ≥50% (Fig. 1C), LDH ≥1519, β2M ≥ 4, hemoglobin <14 and platelet count <63,000 had increased risk of death. In MVA, factors significantly associated with inferior OS in AH-MCL were age (>72 yrs), t-MCL category, Ki-67% ≥50%, ECOG-PS (1-4 compared to 0). Presence of t-MCL, high Ki-67%, CNS involvement were predictive of inferior FFS. Pts who received ibrutinib based or R-HCVAD based therapies had lower hazard ratio for FFS. Subset analysis of blastoid vs pleomorphic MCL did not reveal any significant difference in clinical features of survival but FFS was inferior in pleomorphic category. Frequently mutated genes in AH-MCL were ATM, CCND1, NOTCH1, KMT2D, KMT2C, TP53, SPEN, SMARCA4 and NSD2. There was no statistically significant difference in the mutation profile of dnMCL vs t-MCL. Significant differences in the mutation burden between pts with high Ki-67 (≥50%) and those with low Ki-67%, were noted - ATM (p = 0.001), CCND1 (p<0.001), NOTCH1(p = 0.001), TP53 (p = 0.006), SMARCA4 (p = 0.006), NSD2 (p = 0.02), NOTCH3 (p = 0.02) Figure-1E. Keywords: mantle cell lymphoma (MCL)." @default.
- W2950791822 created "2019-06-27" @default.
- W2950791822 creator A5004970562 @default.
- W2950791822 creator A5009603653 @default.
- W2950791822 creator A5012265487 @default.
- W2950791822 creator A5015633466 @default.
- W2950791822 creator A5021496101 @default.
- W2950791822 creator A5023630161 @default.
- W2950791822 creator A5027450560 @default.
- W2950791822 creator A5042491282 @default.
- W2950791822 creator A5042610364 @default.
- W2950791822 creator A5042663456 @default.
- W2950791822 creator A5053389143 @default.
- W2950791822 creator A5053926894 @default.
- W2950791822 creator A5054301773 @default.
- W2950791822 creator A5059373442 @default.
- W2950791822 creator A5063211679 @default.
- W2950791822 creator A5065960669 @default.
- W2950791822 creator A5067050513 @default.
- W2950791822 creator A5070489123 @default.
- W2950791822 creator A5073124389 @default.
- W2950791822 creator A5077388805 @default.
- W2950791822 creator A5078053625 @default.
- W2950791822 creator A5078458883 @default.
- W2950791822 creator A5082828336 @default.
- W2950791822 creator A5089736242 @default.
- W2950791822 creator A5091186786 @default.
- W2950791822 date "2019-06-01" @default.
- W2950791822 modified "2023-10-14" @default.
- W2950791822 title "COMPREHENSIVE ANALYSIS OF PROGNOSTIC FACTORS, OUTCOMES AND MUTATION PROFILE IN PATIENTS WITH AGGRESSIVE HISTOLOGY (BLASTOID/PLEOMORPHIC) OR TRANSFORMED MANTLE CELL LYMPHOMA" @default.
- W2950791822 doi "https://doi.org/10.1002/hon.49_2630" @default.
- W2950791822 hasPublicationYear "2019" @default.
- W2950791822 type Work @default.
- W2950791822 sameAs 2950791822 @default.
- W2950791822 citedByCount "0" @default.
- W2950791822 crossrefType "journal-article" @default.
- W2950791822 hasAuthorship W2950791822A5004970562 @default.
- W2950791822 hasAuthorship W2950791822A5009603653 @default.
- W2950791822 hasAuthorship W2950791822A5012265487 @default.
- W2950791822 hasAuthorship W2950791822A5015633466 @default.
- W2950791822 hasAuthorship W2950791822A5021496101 @default.
- W2950791822 hasAuthorship W2950791822A5023630161 @default.
- W2950791822 hasAuthorship W2950791822A5027450560 @default.
- W2950791822 hasAuthorship W2950791822A5042491282 @default.
- W2950791822 hasAuthorship W2950791822A5042610364 @default.
- W2950791822 hasAuthorship W2950791822A5042663456 @default.
- W2950791822 hasAuthorship W2950791822A5053389143 @default.
- W2950791822 hasAuthorship W2950791822A5053926894 @default.
- W2950791822 hasAuthorship W2950791822A5054301773 @default.
- W2950791822 hasAuthorship W2950791822A5059373442 @default.
- W2950791822 hasAuthorship W2950791822A5063211679 @default.
- W2950791822 hasAuthorship W2950791822A5065960669 @default.
- W2950791822 hasAuthorship W2950791822A5067050513 @default.
- W2950791822 hasAuthorship W2950791822A5070489123 @default.
- W2950791822 hasAuthorship W2950791822A5073124389 @default.
- W2950791822 hasAuthorship W2950791822A5077388805 @default.
- W2950791822 hasAuthorship W2950791822A5078053625 @default.
- W2950791822 hasAuthorship W2950791822A5078458883 @default.
- W2950791822 hasAuthorship W2950791822A5082828336 @default.
- W2950791822 hasAuthorship W2950791822A5089736242 @default.
- W2950791822 hasAuthorship W2950791822A5091186786 @default.
- W2950791822 hasConcept C126322002 @default.
- W2950791822 hasConcept C142724271 @default.
- W2950791822 hasConcept C143998085 @default.
- W2950791822 hasConcept C2775912362 @default.
- W2950791822 hasConcept C2777525834 @default.
- W2950791822 hasConcept C2779338263 @default.
- W2950791822 hasConcept C2780007613 @default.
- W2950791822 hasConcept C57742111 @default.
- W2950791822 hasConcept C71924100 @default.
- W2950791822 hasConcept C90924648 @default.
- W2950791822 hasConceptScore W2950791822C126322002 @default.
- W2950791822 hasConceptScore W2950791822C142724271 @default.
- W2950791822 hasConceptScore W2950791822C143998085 @default.
- W2950791822 hasConceptScore W2950791822C2775912362 @default.
- W2950791822 hasConceptScore W2950791822C2777525834 @default.
- W2950791822 hasConceptScore W2950791822C2779338263 @default.
- W2950791822 hasConceptScore W2950791822C2780007613 @default.
- W2950791822 hasConceptScore W2950791822C57742111 @default.
- W2950791822 hasConceptScore W2950791822C71924100 @default.
- W2950791822 hasConceptScore W2950791822C90924648 @default.
- W2950791822 hasIssue "S2" @default.
- W2950791822 hasLocation W29507918221 @default.
- W2950791822 hasOpenAccess W2950791822 @default.
- W2950791822 hasPrimaryLocation W29507918221 @default.
- W2950791822 hasRelatedWork W1991449184 @default.
- W2950791822 hasRelatedWork W2171422777 @default.
- W2950791822 hasRelatedWork W2348836856 @default.
- W2950791822 hasRelatedWork W2369117338 @default.
- W2950791822 hasRelatedWork W2371593350 @default.
- W2950791822 hasRelatedWork W2410644446 @default.
- W2950791822 hasRelatedWork W2416406993 @default.
- W2950791822 hasRelatedWork W2418591842 @default.
- W2950791822 hasRelatedWork W645779997 @default.
- W2950791822 hasRelatedWork W74504067 @default.
- W2950791822 hasVolume "37" @default.
- W2950791822 isParatext "false" @default.
- W2950791822 isRetracted "false" @default.